Results 21 to 30 of about 1,556 (222)

IMPDH inhibition enhances cytarabine efficacy in SAMHD1‐expressing leukaemia cells via guanine nucleotide depletion

Molecular Oncology, EarlyView.
Cytarabine is a key therapy for acute myeloid leukaemia (AML), but its efficacy is limited by the dNTPase SAMHD1, which hydrolyses its active metabolite. Screening nucleotide biosynthesis inhibitors revealed that IMPDH inhibitors selectively sensitise SAMHD1‐proficient AML cells to cytarabine.
Miriam Yagüe‐Capilla, Christopher Dirks, Caroline Eiden, Sonja K. Fesenmayer, Femke M. Hormann, Yolande Klootsema, Ingrid Lilienthal, Si Min Zhang, Nikolas Herold, Sean G. Rudd   +9 more
wiley   +1 more source

Longitudinal circulating tumor DNA profiling in patients with advanced endometrial cancer using an off‐the‐shelf targeted NGS panel

Molecular Oncology, EarlyView.
Intratumour heterogeneity complicates precision management of advanced endometrial cancer. Circulating tumor DNA (ctDNA) offers a minimally invasive strategy to capture tumor evolution and therapeutic resistance. Here, we compare tumor‐agnostic NGS with tumor‐informed ddPCR, outlining their relative sensitivity, concordance, and clinical implications ...
Carlos Casas‐Arozamena, Karin Teien Lande, Eva Diaz, Ana Vilar, Juan Cueva, Efigenia Arias, Victoria Sampayo, Alicia Abalo, Nerea González, Eva Colás, Antonio Gil‐Moreno, Miguel Abal, Gema Moreno‐Bueno, Therese Sørlie, Kristina Lindemann, Laura Muinelo‐Romay   +15 more
wiley   +1 more source

Anti-periodic solutions for nonlinear evolution inclusions

Journal of Evolution Equations, 2018
The authors consider the nonlinear anti-periodic evolution inclusion \[ \begin{aligned} & -u'(t)\in A(t,u(t))+F(t,u(t))\text{ a.e. on }I=[0,T],\\ & u(0)=-u(T),\end{aligned}\eqno{(1)} \] where \(\left( X,H,X^{\ast }\right) \) is an evolution triple, \(A:I\times X\rightarrow 2^{X^{\ast }}\) and \(F:I\times X\rightarrow 2^{H}\). \ It is not assumed that \(
Gasiński, Leszek, Papageorgiou, Nikolaos S.   +1 more
openaire   +2 more sources

Longitudinal genome‐wide aneuploidy measurements in circulating cell‐free DNA to predict lack of benefit from pembrolizumab in patients with metastatic urothelial cancer

Molecular Oncology, EarlyView.
Many patients with urothelial cancer do not benefit from treatment with pembrolizumab, while at risk of severe side effects. Changes in the levels of circulating tumor DNA early during treatment, measured by a simple and affordable assay that can be easily implemented in the clinic, can be used as a prognostic tool to identify these patients.
Youssra Salhi, Stavros Makrodimitris, Sandra van Wilpe, Iris te Paske, Vanja de Weerd, Corine M. Beaufort, Hans M. Westgeest, Jens Voortman, Maureen J. B. Aarts, Maud Rijnders, Astrid A. M. van der Veldt, Ronald de Wit, Niven Mehra, Saskia M. Wilting, Debbie G. J. Robbrecht   +14 more
wiley   +1 more source

A novel quinazolinone insulin receptor inhibitor and its synergy with an EGFR inhibitor in glucose‐driven glioblastoma

Molecular Oncology, EarlyView.
The novel styrylquinazolinone‐based molecule W1B effectively suppresses glioblastoma by inhibiting IGF1R and EGFR. In high‐glucose microenvironments driving tumor resistance, W1B acts synergistically with the EGFR inhibitor dacomitinib. This combination safely blocks compensatory survival signaling in zebrafish xenograft models. Showcasing promising in
Patryk Rurka, Wioleta Cieślik, Wojciech Płaziński, Katarzyna Stępnik, Anna Boguszewska‐Czubara, Elżbieta Kot, Robert Musioł, Mateusz Jasica, Anna Mrozek‐Wilczkiewicz, Katarzyna Malarz   +9 more
wiley   +1 more source

Strong nonlinear functional-differential variational inequalities: problems without initial conditions

Frontiers in Applied Mathematics and Statistics
Problems without initial conditions for evolution equations and variational inequalities appear in the modeling of different non-stationary processes within many fields of science, such as ecology, economics, physics, cybernetics, etc., if these ...
Mykola Bokalo, Iryna Skira, Taras Bokalo
doaj   +1 more source

On the “bang-bang” principle for nonlinear evolution inclusions

Aequationes Mathematicae, 1993
This paper appears to be (verbatim) the same as [Aequationes Math. 45, No. 2-3, 267-280 (1993) see the review above].
openaire   +2 more sources

Inhibition of cyclin‐dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation

Molecular Oncology, EarlyView.
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington, Divya L. Dayanidhi, Mohammad Zokaasadi, John B. Mantyh, Pelumi D. Olawuni, Gabrielle Rupprecht, Jeremy M. Force, Shannon McCall, Ashwani K. Bahl, David S. Hsu, Jason A. Somarelli   +10 more
wiley   +1 more source

Generalized frameworks for first-order evolution inclusions based on Yosida approximations

Electronic Journal of Differential Equations, 2011
First, general frameworks for the first-order evolution inclusions are developed based on the A-maximal relaxed monotonicity, and then using the Yosida approximation the solvability of a general class of first-order nonlinear evolution inclusions is ...
Ram U. Verma
doaj  

On the set of solutions of a class of nonlinear evolution inclusions [PDF]

Kodai Mathematical Journal, 1992
The present paper deals with properties of the solution set of the Cauchy problem for nonlinear evolution inclusions of the form \(x'(t)\in A(t,x(t))+f(t)\), a.e., and \(x'(t)\in A(t,x(t))+F(t,x(t))\), a.e., where \(A\) and \(F\) are multivalued mappings.
openaire   +2 more sources